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Abstract
Familial hemiplegic migraine type 1 (FHM1) is a rare migraine subtype. Whereas transgenic knock-in mice with the human
pathogenic FHM1 R192Q missense mutation in the Cacna1a gene reveal overall neuronal hyperexcitability, the effects on
the trigeminovascular system and calcitonin gene-related peptide (CGRP) receptor are largely unknown. This gains
relevance as blockade of CGRP and its receptor are therapeutic targets under development. Hence, we set out to
test these effects in FHM1 mice. We characterized the trigeminovascular system of wild-type and FHM1 mice through: (i)
in vivo capsaicin- and CGRP-induced dural vasodilation in a closed-cranial window; (ii) ex vivo KCl-induced CGRP release
from isolated dura mater, trigeminal ganglion and trigeminal nucleus caudalis; and (iii) peripheral vascular function in vitro.
In mutant mice, dural vasodilatory responses were significantly decreased compared to controls. The ex vivo release of
CGRP was not different in the components of the trigeminovascular system between genotypes; however, sumatriptan
diminished the release in the trigeminal ganglion, trigeminal nucleus caudalis and dura mater but only in wild-type mice.
Peripheral vascular function was similar between genotypes. These data suggest that the R192Q mutation might be
associated with trigeminovascular CGRP receptor desensitization. Novel antimigraine drugs should be able to revert this
complex phenomenon.
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Introduction
Migraine is a disabling neurovascular brain disorder
that is characterized by severe attacks of throbbing
headache, which can be accompanied by nausea, vomit-
ing, osmo-, photo-, and phonophobia.1 In one-third of
patients, attacks may be preceded by neurological
symptoms (migraine with aura), the likely consequence
of a wave of neuronal and glial depolarization with
subsequent temporary inactivity, called cortical spreading
depression.2 Migraine headache is associated with activa-
tion of the trigeminovascular system and calcitonin gene-
related peptide (CGRP) release from sensory nerves.3
Monogenic familial hemiplegic migraine, a rare subtype
of migraine with transient hemiparesis during the aura,
has shown validity as a genetic model of migraine.4
Familial hemiplegic migraine type 1 (FHM1) is caused
by speciﬁc missense mutations in the Cacna1a gene that
encodes the a1A subunit of neuronal voltage-gated
CaV2.1 (P/Q-type) calcium channels.
5,6
1Department of Internal Medicine, Division of Vascular Medicine and
Pharmacology, Erasmus MC, Rotterdam, the Netherlands
2Departments of Neurology and Human Genetics, Leiden University
Medical Center, Leiden, the Netherlands
Corresponding author:
Antoinette MaassenVanDenBrink, Department of Internal Medicine,
Division of Pharmacology, Erasmus Medical Center, P.O. Box 2040, 3000
CA Rotterdam, The Netherlands
Email: a.vanharen-maassenvandenbrink@erasmusmc.nl
Journal of Cerebral Blood Flow &
Metabolism
0(00) 1–12
! Author(s) 2017
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/0271678X17725673
journals.sagepub.com/home/jcbfm
A transgenic knock-in mouse model was generated
by introducing the human FHM1 R192Q mutation into
the mouse Cacna1a gene using a gene targeting
approach.7 The mutation results in a gain of CaV2.1
channel function with enhanced cortical glutamatergic
neurotransmission,8 an increased susceptibility to cor-
tical spreading depression,7,9 and signs of spontaneous
unilateral head pain, as evidenced by increased head
grooming and eye blinking.10 Few studies have investi-
gated CGRP expression and function in the trigemino-
vascular system of FHM1 R192Q mice; however, the
results are inconsistent and mostly only the trigeminal
ganglion was investigated,11–13 making it diﬃcult to
understand the exact role of this mutation in the diﬀer-
ent components of the trigeminal system. Furthermore,
the eﬀect the R192Q mutation may have on perivascu-
lar CGRP release and CGRP-induced (dural artery)
vasodilation has not been investigated. Also, it is not
known whether the R192Q mutation could aﬀect the
peripheral vascular function.
Hence, to study the eﬀects of the R192Q mutation
on the trigeminovascular system, we investigated in
FHM1 R192Q mice: (i) trigeminovascular dural vaso-
dilation induced by endogenous and exogenous CGRP
in vivo, (ii) CGRP release in the trigeminovascular com-
ponents including the trigeminal nucleus caudalis, tri-
geminal ganglion and dura mater ex vivo, and (iii)
peripheral vascular CGRP receptor function in vitro.
We hypothesized that the R192Q mutation will increase
dural vasodilation and CGRP release in the trigemino-
vascular system but will not disturb peripheral vascular
function.
Material and methods
Experimental animals
Experiments were performed in 13- to 14-week-old
homozygous FHM1 R192Q mice (‘‘R192Q’’) and
wild-type littermates (‘‘wild-type’’) of both sexes.
Mice were backcrossed for at least ﬁve generations
with C57BL/6J mice so that the genetic background is
>97% C57BL/6J, as described before.7 All mice were
bred at the Leiden University Medical Center and
transported to our animal facility at least 14 days
before the start of the experiment to allow for suﬃcient
equilibration time at the Erasmus MC. Animals were
housed under a 12-h dark-light cycle and given free
access to food and water. All experiments were
approved by the Erasmus University Medical Center’s
institutional animal ethics committee and in accordance
with the European directive 2010/63/EU and ARRIVE
(Animal Research: Reporting in Vivo Experiments)
reporting guidelines for the care and use of laboratory
animals.
In vivo: Intravital microscopy and dural artery
vasodilation
Animals (n¼ 32; 13 wild-type and 19 R192Q) were
anaesthetized throughout the experiment using intra-
peritoneal (i.p.) sodium pentobarbital (80mg/kg,
i.p. and then 20mg/kg/h, i.p.). The trachea was
cannulated and connected to a pressure ventilator
(small animal ventilator SAR-830 series; CWE, Inc.,
Ardmore, PA, USA). The jugular vein was cannulated
for intravenous (i.v.) administration of drugs and the
femoral artery for continuous monitoring of mean
arterial pressure. During the experiment, the core
temperature of the animal was monitored via a
rectal thermometer and maintained between 36.5 and
37.5C using a homeothermic blanket system for
rodents (Harvard Instruments, Edenbridge, UK).
Subsequently, the mouse was placed in a stereotaxic
frame, and the parietal bone was drilled thin until the
dural artery was clearly visible. As the mouse skull
is very thin, care was taken to drill with constant
application of ice-cold saline. In four out of 32 mice,
bleeding was observed underneath the skull, making
visualization of the artery diﬃcult; these animals were
excluded from the study. The drilled area was covered
with mineral oil to prevent drying of the skull and
to facilitate visualization of the artery. The dural
artery was captured with an intravital microscope
(Leica MZ 16; Leica Microsystem Ltd, Heerbrugg,
Switzerland), using a cyan ﬁlter on a cold source of
light. A zoom lens (80magniﬁcation) and camera
(DCx V3.52, Thorlabs LTD, Ely, UK) were used to
capture the image of the dural artery, which was
displayed and measured on a computer using a dedi-
cated software package (IDA-Intravital Dimension
Analyser; http://www.beneryx.co.uk) integrated
with a ADC/DAC board (DI-158, DATAQ instru-
ments, ‘s-Hertogenbosch, The Netherlands). Data
of dural artery diameter, mean arterial pressure
and exhaled CO2 were recorded using Labchart
data acquisition system (AD Instruments Ltd,
Oxford, UK).
As described in a previous study,14 mice dural
arteries were ﬁrst constricted with endothelin-1
(ET-1) before other pharmacological interventions, as
it is not possible to observe signiﬁcant vasodilation in
mouse dural arteries without artery preconstriction.
ET-1 (1–6mg/kg i.v.) was titrated to induce vasocon-
striction, reducing the diameter to 30–40% of its ori-
ginal diameter. Capsaicin (30 mg/kg) and a-CGRP
(10 mg/kg) were administrated i.v. as a bolus after
the constriction induced by ET-1 was stable (around
5 minutes). The arterial diameter was recorded for
another 10min; 30min were allowed to elapse after
each of the treatments for the recovery of baseline
diameter.
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Ex vivo: CGRP release in trigeminal nucleus
caudalis, trigeminal ganglion, and dura mater
Mice were anesthetized using sodium pentobarbital
(80mg/kg, i.p.) and decapitated at the atlanto-occipital
joint. The skin and galea aponeurotica were retracted
from the skull, which was divided into halves by a clear
cut along the sagittal suture. The brain halves, together
with the brainstem, were carefully removed while the
cranial dura was left attached to the skull.15 The tri-
geminal nucleus caudalis (Sp5C), which runs caudally
from approximately 9–13mm from bregma, was iso-
lated from the brainstem. The trigeminal ganglia were
harvested by dissection 1mm proximal and distal to the
point where the mandibular nerve branches oﬀ and the
dura mater around the trigeminal ganglion had been
carefully removed.16 All other tissues, except for the
dura mater, were extracted from the skull without
damaging the dura. The isolated trigeminal nucleus
caudalis, trigeminal ganglion and the skull with the
dura mater were immersed and washed in carbogenated
synthetic interstitial ﬂuid, containing (mM): NaCl
(108), KCl (3.48), MgSO4 (3.5), NaHCO3 (26),
NaH2PO4 (11.7), CaCl2 (1.5), sodium gluconate (9.6),
glucose (5.55) and sucrose (7.6) for 30min at 37C.
Isolated trigeminal nucleus caudalis, trigeminal gan-
glion and dura mater were placed in a 24-well plate
containing 500 mL synthetic interstitial ﬂuid. The
24-well plate was ﬁxed in a water bath that formed a
closed humid chamber of 37C. To induce CGRP
release, tissues were stimulated with 60mM KCl, this
concentration was chosen based on previous literature
on CGRP release in rats and mice.17 To test reprodu-
cibility, a second stimulation with 60mM KCl was
done after two wash steps of 10min each. In the
experiments with sumatriptan (30 mM), the agonist
was applied 10min prior to the challenge with
60mM KCl. For every sample, including basal, the
solution was collected after 10min incubation and
mixed with aprotinin (500KUI/mL; n¼ 6–12). For
the assessment of CGRP content, samples were
stored at 80C until processed with a commercial
CGRP RIA kit according to the manual (Phoenix
Pharmaceuticals, Burlingame, CA, USA). The assay
has a detection level of 0.1 pg/mL, if the CGRP
content of a sample was below the detection limit,
the value for that sample was set at 0.1 pg/mL.
In vitro: Peripheral vascular function
Aortas and mesenteric arteries were dissected from the
mice and placed in a carbogenated Krebs bicarbonate
buﬀer solution containing (mM): NaCl (118), KCl
(4.7), CaCl2 (2.5), MgSO4 (1.2), KH2PO4 (1.2),
NaHCO3 (25) and glucose (8.3); pH 7.4. The arteries
were cut in small segments of about 2–4mm each,
which were suspended in Mulvany myographs
(ADinstruments, Danish Myograph Technology,
Aarhus, Denmark) containing oxygenated Krebs bicar-
bonate solution at 37C. After equilibration for at least
30 min, with two changes of solution at 15-min inter-
vals, blood vessel segments were subsequently stretched
to a tension normalized to 90% of l100.
18 Then, the
vessels were exposed to 30mM KCl. The maximum
contractile response to KCl was determined using
100mM KCl. After washout and stabilisation, concen-
tration-response curves to a-CGRP, acetylcholine,
sodium nitroprusside and 5-hydroxytryptamine
(5-HT) were constructed in a parallel design,19
U46619 (10-300 nM) was used to induce precontraction
of the vessel segments, before constructing relaxation
curves to acetylcholine, sodium nitroprusside and
a-CGRP. After the concentration-response curves to
acetylcholine, a single concentration of sodium nitro-
prusside (0.1mM) was administered.
Data analysis
Dural artery diameter was calculated from the area
under the curve of the intensity measured and expressed
in arbitrary units (AU). Vasodilation induced by cap-
saicin or a-CGRP was corrected for diameter change
before induction of vasodilation to compare diﬀerences
between wild-type and mutant mice. Changes in mean
arterial pressure were expressed in mm Hg.20 Paired
and unpaired student t-tests and one-way ANOVA
were conducted to compare changes in dural diameter
and blood pressure after each experimental interven-
tion, followed by the Bonferroni multiple comparisons
post-test.
CGRP samples were measured in duplicate and total
CGRP release was calculated as the average of the
duplicates. CGRP release was expressed as relative sti-
mulated CGRP release, which was calculated by the
ratio of KCl-induced CGRP release and basal CGRP
release.12 Statistical diﬀerences of the relative CGRP
release between genotypes were calculated using one-
tailed Mann–Whitney test for unpaired observations
and Friedmann test, followed by Dunns multiple com-
parison post hoc test. For the repeated stimulation with
KCl and the sumatriptan experiments, a one-tailed
Wilcoxon matched pairs test for non-parametric ana-
lysis of paired data was used.
Vasorelaxant responses to a-CGRP, acetylcholine
and sodium nitroprusside were expressed relative to
the contraction induced by U46619 (10 nM–100 nM).
Contraction by 5-HT was expressed relative to the con-
traction induced by KCl (100mM). For each agonist,
the maximal eﬀect (Emax) was calculated. The concen-
tration-response curves of the agonists were analyzed
using nonlinear regression analysis, and the potency of
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the agonists was expressed as pEC50 (i.e. negative loga-
rithm of the molar concentration of agonist inducing
half maximum response) using GraphPad Prism 5.0
(GraphPad Software Inc., San Diego, CA, USA).
Statistical diﬀerences of the Emax and pEC50 were cal-
culated using the unpaired student t-test.21
While the experimenter was aware of the genotype of
the animals during the experiment because of logistic
reasons, all analyses were performed in a manner
blinded to the genotype. All data are expressed as
meanSEM. Statistical signiﬁcance was accepted at
p< 0.05
Compounds
The compounds used in the present study (obtained
from the sources indicated) were: rat a-CGRP and
ET-1 (NeoMPS S.A., Strasbourg, France), sumatriptan
succinate, capsaicin, acetylcholine, sodium nitroprus-
side and 5-HT (Sigma Chemical Co., Steinheim,
Germany). a-CGRP, ET-1, sumatriptan, acetylcholine,
sodium nitroprusside and 5-HT were dissolved in
water. Capsaicin (1mg/mL) was dissolved in a mixture
of Tween-80, ethanol 70% and water (1:1:8). All stock
solutions were stored at 80C until required.
Just before use, the stock solutions were further diluted
to appropriate concentrations in isotonic saline for
injection and in water for application.
Results
General
There was no diﬀerence in body weight between the
wild-type (22.4 1.0 g) and R192Q (24.6 1.2) mice
included in our study (p¼ 0.807). Also, in none of the
experiments, there was a diﬀerence between the results
obtained in male and female animals. Therefore, the
results from both sexes were pooled for further
analysis.
In vivo: Effect on dural artery dilation induced
by capsaicin and CGRP
A trace obtained during an experiment is shown in
Figure 1. Diameter changes induced by ET-1, capsaicin
or CGRP are shown in Figure 2. Blood vessel baseline
diameter before any pharmacological intervention was
signiﬁcantly higher in the wild-type (721 48 AU;
n¼ 12) than mutant (560 53 AU; n¼ 16, p< 0.05)
Figure 1. A trace obtained during an experiment on the closed-cranial window. The upper red line represents the dural artery
diameter (in arbitrary units, AU) and the lower blue line represents the blood pressure (in mm Hg) simultaneously measured in the
femoral artery. The gray vertical lines represent the moment of intravenous administration of endothelin-1 (ET-1, 2mg/kg), capsaicin
(30 mg/kg) or CGRP (10 mg/kg).
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mice. Administration of ET-1 reduced the dural artery
diameter in the capsaicin-treated group to 40 3% and
31 4% of its original diameter in wild-type and
mutant mice, respectively. In the CGRP-treated
group, ET-1 reduced the diameter to 37 6% of its
original diameter in wild-type mice and to 34 9% of
its original diameter in the mutant mice. There was no
signiﬁcant diﬀerence between the two genotypes in the
dose of ET-1 required to reach this preconstriction
(wild-type: 3.3 0.6mg/kg; n¼ 22 vs. R192Q: 3.7
0.4mg/kg; n¼ 27; p¼ 0.174).
Capsaicin induced signiﬁcant (p< 0.001) dural
vasodilation in wild-type (88 4%) and mutant
(53 6%) mice compared to the preconstriction.
Capsaicin-induced vasodilation corrected for the
diameter change before induction of vasodilation
was signiﬁcantly lower in the mutant mice (22 4%;
n¼ 16) than in the wild-type (48 5%; n¼ 11;
p< 0.001).
CGRP-induced dural vasodilation was signiﬁcantly
diﬀerent compared to the preconstriction in wild-type
(68 6%; n¼ 11; p< 0.01), showing a tendency for sig-
niﬁcance in mutant mice (46 9%; n¼ 11; p¼ 0.06).
In accordance, CGRP-induced vasodilation corrected
for the diameter change before induction of vasodila-
tion was also signiﬁcantly lower in mutant mice
(11 5%; n¼ 11) than in the wild-type (31 7%;
n¼ 11; p< 0.05).
In vivo: Effect on mean arterial pressure of
capsaicin and CGRP
As shown in Figure 3, baseline mean arterial pressure
was comparable between the two genotypes (wild-type:
80 3mm Hg; n¼ 10 vs. R192Q: 72 4mmHg; n¼ 14;
p¼ 0.11). ET-1 increased the mean arterial pressure
similarly in both genotypes (wild-type: 111 7mm
Hg; n¼ 10 vs. R192Q: 107 6mm Hg; n¼ 14;
p< 0.001 vs. baselines). Capsaicin did not reverse the
elevated blood pressure caused by ET-1 in either geno-
type (wild-type: 100 7mm Hg; n¼ 10 vs. R192Q:
102 5mm Hg; n¼ 14). Administration of CGRP
caused a normalization of the elevated blood pressure
in both genotypes (wild-type: 80 5mm Hg; n¼ 9, vs.
R192Q: 89 5mm Hg; n¼ 10; p< 0.001 vs. baselines).
Mean arterial pressure changes induced by ET-1, cap-
saicin or CGRP were not diﬀerent between wild-type
and mutant mice.
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Figure 2. Trigeminovascular dural artery vasodilation. Diameter change (%) induced by endothelin-1 (ET-1), capsaicin or CGRP in
wild-type (WT, white bars) and R192Q (grey bars) mice. ET-1 induced comparable dural vasoconstriction in all groups (upper left and
right panels). Capsaicin induced significant dural vasodilation in both genotypes (upper left panel), while CGRP only induced dural
vasodilation in the wild-type group (upper right panel). The vasodilation induced by capsaicin and CGRP, corrected for the ET-1
baseline, is significantly lower in the R192Q groups than in the wild-type groups (lower left and right panel). Data are expressed as
mean SEM, n¼ 9–16, *p< 0.05 vs. the corresponding dose to ET-1, #p< 0.05 between genotypes.
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Ex vivo: Relative stimulated CGRP release
after KCl stimulation
Basal CGRP release (in absolute values) in trigeminal
caudal nucleus (wild-type: 4.9 1.0; n¼ 11 vs. R192Q:
6.2 1.3 n¼ 12; p¼ 0.203), trigeminal ganglion (wild-
type: 1.3 0.3; n¼ 11 vs. R192Q: 1.3 0.2 n¼ 12;
p¼ 0.367) and dura mater (wild-type: 0.9 0.6; n¼ 12
vs. R192Q: 1.0 0.2 n¼ 12; p¼ 0.321) was not diﬀerent
between wild-type and mutant mice. Relative stimu-
lated CGRP release (measured as the ratio of KCl-
induced CGRP release and CGRP release at basal)
was used to compare the eﬀect of KCl in the diﬀerent
trigeminal components of wild-type and mutant mice
(Figure 4).Relative stimulated CGRP release induced
by KCl was comparable between wild-type and
mutant mice in the trigeminal nucleus caudalis (wild-
type: 3.6 0.5; n¼ 12 vs. R192Q: 4.1 0.8; n¼ 11;
p¼ 0.415), trigeminal ganglion (wild-type: 3.6 0.8;
n¼ 12 vs. R192Q: 3.4 0.9; n¼ 12; p¼ 0.375), and
dura mater (wild-type: 9.0 2.7; n¼ 12 vs. R192Q:
5.6 1.3; n¼ 12; p¼ 0.425). Moreover, there was no
diﬀerence in relative stimulated CGRP release between
the diﬀerent trigeminovascular components of wild-
type and mutant mice.
Ex vivo: Relative stimulated CGRP release
after repeated stimulation with KCl
CGRP release was measured after the ﬁrst and second
stimulation with KCl to test the reproducibility of
CGRP release. The relative stimulated CGRP release
of wild-type mice was similar for the ﬁrst and second
stimulation for trigeminal nucleus caudalis (1st:
3.7 0.8 vs. 2nd: 1.8 0.3; n¼ 6; p¼ 0.156), trigeminal
ganglion (1st: 3.9 1.7 vs. 2nd: 3.0 1.2; n¼ 6;
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Figure 3. Effect of pharmacological intervention on mean arterial pressure. Mean arterial pressure (MAP; mm Hg) after adminis-
tration of endothelin-1 (ET-1), capsaicin or CGRP in wild-type (white bars) and R192Q (grey bars) mice. ET-1 increased the MAP
compared to the baseline in both genotypes, and this increase was reverted after administration of only CGRP. Data are expressed as
mean SEM, n¼ 9–14, *p< 0.05.
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Figure 4. CGRP release in the trigeminovascular system. Relative stimulated CGRP release in the trigeminal nucleus caudalis (TNC),
trigeminal ganglion (TG) and dura mater of wild-type (WT, white bars and circles) and R192Q (grey bars and squares) mice. There is
no statistical difference in CGRP release between wild-type and R192Q mice in the trigeminal nucleus caudalis, trigeminal ganglion or
dura mater. Data are expressed as mean SEM, n¼ 11–12.
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p¼ 0.281) and dura mater (1st: 2.4 0.7 vs. 2nd:
2.2 1.5; n¼ 6; p¼ 0. 281) (Figure 5, top panel). Also
for the mutant mice, no statistical diﬀerences were
observed between the ﬁrst and second stimulation for
trigeminal nucleus caudalis (1st: 4.3 1.1 vs. 2nd:
3.8 2.2; n¼ 6; p¼ 0.406), trigeminal ganglion (1st:
3.7 1.6 vs. 2nd: 6.3 3.2; n¼ 6; p¼ 0.422) and dura
mater (1st: 3.6 0.8 vs. 2nd: 6.4 2.6; n¼ 6; p¼ 0.156)
(Figure 5, top panel), although there was a trend for
increased release in trigeminal ganglion and dura mater,
with means 77% and 78% higher with the 2nd stimu-
lation lowered release for all other tissues in wild-type
or mutant.
Ex vivo: Relative stimulated CGRP release in
the absence and presence of sumatriptan
The eﬀect of pretreatment with sumatriptan (30mM) on
CGRP release in the trigeminovascular components is
shown in Figure 5 (lower panel). In the presence of suma-
triptan, relative stimulated CGRP release in wild-type
mice was signiﬁcantly attenuated in trigeminal nucleus
caudalis (4.7 1.1 vs. 2.6 1.0; n¼ 6; p< 0.05), dura
mater (2.4 0.4 vs. 0.8 0.1; n¼ 5 p< 0.05) and in the
trigeminal ganglion (3.7 1.1 vs. 1.6 0.3; n¼ 6;
p< 0.05). However, in mutant mice, sumatriptan did
not signiﬁcantly reduce the relative stimulated CGRP
release in trigeminal nucleus caudalis (5.3 1.3 vs.
3.4 1.0; n¼ 6; p¼ 0.078), trigeminal ganglion (1.8
0.2 vs. 7.0 3.0; n¼ 6; p¼ 0.078) or dura mater
(4.8 2.2 vs. 5.6 3.2; n¼ 6; p¼ 0.422), although, in
contrast to our hypothesis, there was a trend for
increased release in trigeminal ganglion and dura mater,
with means 390% and 16% higher, whereas sumatriptan
lowered release for the other tissues in wild-type or
mutant.
In vitro: Peripheral vascular function in aortas
and mesenteric arteries
In the aortas, KCl-induced contraction was not diﬀer-
ent between both genotypes (wild-type: 8.3 0.4mN;
n¼ 12 vs. R192Q: 7.9 0.5mN; n¼ 11; p¼ 0.560),
while in mesenteric arteries, the KCl-induced contrac-
tion was signiﬁcantly lower in mutant mice (wild-type:
5.7 0.8mN; n¼ 9 vs. R192Q: 3.4 0.3mN; n¼ 13;
Figure 5. Effect of repeated stimulation and sumatriptan on CGRP release. Relative stimulated CGRP release after a first (1st) and
second (2nd) stimulation with KCl (panels a, b, c) or in the absence () or presence (þ) of sumatriptan (panels d, e, f) in trigeminal
nucleus caudalis (TNC), trigeminal ganglion (TG) and dura mater of wild-type (WT, circles) and R192Q (squares) mice. There were no
statistically significant differences between the first and second stimulation with KCl in either genotype. Sumatriptan significantly
reduced the relative stimulated CGRP release in the trigeminal nucleus caudalis, dura mater and trigeminal ganglion of wild-type, but
not in all the trigeminovascular components of the R192Q mice tested. Data are expressed as mean SEM, n¼ 5–6, *p< 0.05 vs.
response in the absence of sumatriptan.
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p< 0.01). There were no signiﬁcant diﬀerences between
full concentration-response curves to CGRP, sodium
nitroprusside or acetylcholine in aortas or mesenteric
arteries of both genotypes (Figure 6). To determine the
endothelial function, the maximal eﬀect of acetylcho-
line was corrected for the maximal eﬀect induced by
sodium nitroprusside (0.1mM) in the same vessel seg-
ment. No diﬀerences were found in the acetylcholine/
sodium nitroprusside ratio between genotypes in the
aortas (wild-type: 0.76 0.05; n¼ 11 vs. R192Q:
0.77 0.03; n¼ 10; p¼ 0.812) or in the mesenteric
arteries (wild-type: 0.73 0.10; n¼ 6 vs. R192Q:
0.77 0.06; n¼ 9; p¼ 0.714). 5-HT induced a concen-
tration-dependent contraction, which was not diﬀerent
in aortas of both genotypes. In mesenteric arteries, the
maximal eﬀect induced by 5-HT seemed to be lower in
wild-type than in mutant mice, but this was not statis-
tically signiﬁcant (p¼ 0.13; Figure 6). For the Emax and
pEC50 values of the concentration-response curves, see
Supplementary Table 1.
Discussion
The mechanisms underlying migraine pathophysiology
are not completely elucidated. It seems that migraine
is a disorder of brain sensory processing, characterized
by a generalized neuronal hyperexcitability,22 while
the head pain is thought to be the consequence of acti-
vation of the trigeminovascular system, CGRP release
and sensitization of trigeminal nociceptors. Transgenic
mice harboring the FHM1 R192Q mutation revealed
an overall hyperexcitability phenotype and increased
susceptibility to CSD,4 but whether this mutation
could aﬀect the normal physiology of the trigeminovas-
cular system is unknown. Therefore, the functionality
of the trigeminovascular system was investigated in
transgenic mice that express the FHM1 R192Q mis-
sense mutation in the a1A subunit of voltage-gated
CaV2.1 calcium channels that leads to a gain of func-
tion of these channels by studying: (i) dural artery vaso-
dilation induced by endogenous and exogenous CGRP
in vivo, (ii) CGRP release in various components of the
trigeminovascular system ex vivo, and (iii) peripheral
vascular function in vitro.
Several aspects of the CGRP-related trigeminovas-
cular function were abnormal in the mutant mice. First
of all, the trigeminovascular dural artery vasodilation
in vivo, either by endogenous (induced by capsaicin) or
exogenous CGRP, was reduced. A priori we expected
an increased vasodilation in mutant mice. After all, as
CaV2.1 channels are also expressed on perivascular
nerve endings,23 given the gain of function of the
R192Q mutation on CaV2.1 channels,
7 activation of
the channels would lead to release of CGRP, a potent
vasodilator, and increased vasodilation.24
One possible explanation for the reduced eﬀects on
dural vasodilation is that CGRP release may already be
elevated at basal in mutant mice due to the increased
activity of mutant CaV2.1 channels as proposed in pre-
vious studies.11,25 Therefore, administration or release
(a) (b) (c) (d)
(e) (f) (g) (h)
Figure 6. Peripheral vascular function. Concentration-response curve to different agonists in isolated aortas and mesenteric arteries
of wild-type (WT, open circles) and R192Q (closed circles) mice. There were no differences between wild-type and R192Q mice in
relaxant responses to acetylcholine (a, e), sodium nitroprusside (SNP, b, f) and CGRP (c, g), which are expressed relative to the
contraction induced by U46619, in the aortas (a, b, c) and mesenteric arteries (e, f, g). Contractile responses to 5-hydroxytryptamine
(5-HT, d, h), which are expressed relative to 100mM KCl, in the aortas (d) and mesenteric arteries (h) were also not different
between wild-type and R192Q mice. Data are expressed as mean SEM, n¼ 10–13.
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of CGRP from an exogenous or endogenous source,
may no longer exert an eﬀect in response to a stimulus.
However, more complex mechanisms seem to be
involved, since we observed a lower baseline dural
diameter in the mutant mice in our in vivo study; and
no genotypic diﬀerences in CGRP release, at basal or
after KCl stimulation, in the trigeminovascular compo-
nents in our ex vivo study.
On the other hand, hyperactivity of mutant CaV2.1
channels could potentially lead to CGRP depletion –
already at baseline – as may be concluded from an
immunohistochemistry study that showed reduced
CGRP immunoreactivity in the trigeminal ganglia and
trigeminocervical complex of these mice.13 However, our
data do not seem to support CGRP depletion, since no
statistical diﬀerences in basal CGRP release or CGRP
release after repeated stimulation between the genotypes
were observed. Still, a reduction in response, in their case
for intracellular Ca2þ response, was observed after som-
atosensory stimulation when studying the same R192Q
mouse model, which was ascribed to reduced neurovas-
cular coupling.26
An alternative explanation for the in vivo reduced
dural artery vasodilation response to capsaicin may
be mediated by a change in CGRP receptor function
or expression, since we also observed reduced dural
vasodilation induced by exogenous CGRP in the
mutant mice, which might suggest a desensitization or
downregulation of this receptor. Receptor desensitiza-
tion, as suggested before for CGRP-mediated ATP-
gated P2X3 signaling in FHM1 R192Q mice
25 is more
likely given that CGRP receptor expression on trigem-
inal ganglion neurons was shown to be similar between
genotypes in culture and in situ.27
Hypothetically, the diﬀerent in vivo eﬀects on dural
vasodilation between wild-type and mutant mice could
have been due to changes in mean arterial pressure
associated with the administration of drugs. However,
this is unlikely as changes in blood pressure during
intravenous injection of ET-1, capsaicin or CGRP,
are below the level aﬀecting dural vasodilation in this
experimental model28 and, more importantly, they were
not diﬀerent between wild-type and mutant mice.
When considering the present and previous studies
on FHM1 R192Q mice, the basal release of CGRP and
functionality of the CGRP receptor may change with
age. It is noteworthy that in 11-day-old mutant mice
there is an increased basal and KCl-stimulated CGRP
release from trigeminal ganglia;11 in two-week-old ani-
mals an increased basal CGRP release was identiﬁed;25
whereas in four-week-old mice an increased stimulated
CGRP release but unaﬀected basal CGRP release was
identiﬁed.12 Remarkably, in the present study of 13- to
14-week-old mutant mice, which are young adult mice,
neither an increase in basal nor in KCl-stimulated
CGRP release in the components of the trigeminovas-
cular system (including trigeminal ganglia) was
observed, while in our in vivo experiments, CGRP-
induced dural artery vasodilation was decreased.
Moreover, a reduced CGRP expression was found in
the trigeminal ganglion of ﬁve to eight-month-old
mutant mice in an immunohistochemistry study.13
Therefore, it is tantalizing that the age of the mutant
mice may be a determining factor that could reconcile
the diﬀerent ﬁndings of CGRP release in these studies.
An alternative explanation for the apparent discrep-
ancy between our FHM1 R192Q mice data and the
previously studies mentioned, where an increased
CGRP release was observed in the trigeminal gan-
glion,12 may be the concentration of KCl employed in
the diﬀerent experiments. While Fioretti et al.12 used
35mM KCl to stimulate CGRP release, we used
60mM KCl based on studies showing that this concen-
tration activates calcium channels (including the
CaV2.1 channels);
29 and this induces a signiﬁcant
increase in CGRP release without reaching the maximal
eﬀect in the trigeminal ganglion, trigeminal nucleus
caudalis and dura mater,17 which are essential charac-
teristics for our study. However, we cannot exclude that
using lower concentrations, a diﬀerence in sensitivity to
KCl between wild-type and mutant mice might have
been unmasked.
To assess systemic vascular CGRP receptor desensi-
tization, we performed concentration-response curves to
CGRP in isolated aortas and mesenteric arteries
to understand the eﬀect of the R192Q mutation on
peripheral CGRP receptor function. Interestingly, no
diﬀerences in the relaxant responses were found between
genotypes, so it is unlikely that the R192Q mutation
aﬀects CGRP-induced vasodilation in these vessels.
Though, if desensitization of CGRP receptors occurs
due to a structurally elevated CGRP release (caused by
the gain-of-function of the CaV2.1 calcium channel), it
may only be occurring in dural arteries. Unfortunately,
it is not possible to do functional studies with a Mulvany
myograph, due to the small size of those vessels (outer
diameter< 30mm).
The general vascular function of the aortas and mes-
enteric arteries was also investigated by performing con-
centration-response curves to acetylcholine, sodium
nitroprusside, 5-HT and a single dose of KCl. Between
genotypes, there were no diﬀerences in the acetylcholine
and sodium nitroprusside responses, or the acetylcho-
line/sodium nitroprusside ratio, suggesting that the
R192Q mutation does not inﬂuence peripheral nitric
oxide (NO) endothelium-dependent and -independent
pathways, which seems in line with a lack of eﬀect on
the baseline mean arterial pressure in vivo.
Instead, a decreased KCl-induced contraction in the
mesenteric arteries of mutant mice was observed, which
Chan et al. 9
might suggest that the R192Q mutation (in the CaV2.1
calcium channel) indirectly inﬂuences other channels.
This might also be the case with other voltage-dependent
calcium channels, disturbing the levels of cytoplasmic
[Ca2þ], the activation of the Ca2þ-calmodulin-dependent
myosin light chain (MLC) kinase, MLC phosphoryl-
ation, and overall contraction of the smooth muscle
cells.30 The latter seems to be supported by ﬁndings,
although not conﬁrmed by other research groups, that
the CaV2.1 calcium channel may be present in smooth
muscle cells of murine aortas, rat renal vessels and rabbit
renal aﬀerent arterioles;31,32 and may contribute to con-
traction by regulating intracellular calcium concentra-
tions.32 The fact that this eﬀect was only observed in
mesenteric arteries and not in aortas suggests that the
R192Q mutation in CaV2.1 channels might play a more
prominent role in resistance arteries than in conductance
arteries. This could be related to the channel expression
levels in diﬀerent vascular beds. Since the 5-HT-induced
contraction was related to the KCl response in vitro, the
trend of increased 5-HT-induced contraction observed in
the mesenteric arteries of the R192Q mice, might rather
be due to biological diﬀerences in the KCl responses,
than diﬀerences in the function of the 5-HT1B receptors,
which is responsible for the 5-HT-induced contraction.33
The ex vivo CGRP release experiments demon-
strated in wild-type mice, that the presence of sumatrip-
tan signiﬁcantly reduced CGRP release upon
stimulation in the trigeminal nucleus caudalis, dura
mater and in the trigeminal ganglion. This seems in
line with a ﬁnding that naratriptan and sumatriptan
prevented the induction of sensitization in central tri-
geminovascular neurons, but not from peripheral ter-
minals innervating the dura mater.34 However, there
was also a trend of lower CGRP release in the trigem-
inal nucleus caudalis of wild-type mice after a second
stimulation with KCl (Figure 5, top panel), which
might suggest that the eﬀect of sumatriptan observed
is a result of lower release in response to the second
stimulation, rather than inhibition of CGRP release
by sumatriptan. This is unlikely since delta CGRP
release in the sumatriptan experiments (CGRP release
in the presence of sumatriptan – CGRP release in the
absence of sumatriptan) were signiﬁcantly diﬀerent
from the hypothetical value of zero (p¼ 0.05); which
was not the case for the delta CGRP release in the
repeated experiments (CGRP release after second
stimulation – CGRP release after ﬁrst stimulation),
indicating that the lower CGRP release in the trigem-
inal nucleus caudalis of wild-type mice in the sumatrip-
tan experiments is indeed an eﬀect of sumatriptan.
Notably, in the mutant mice, sumatriptan did not
show a statistically signiﬁcant change in CGRP release
upon stimulation on the diﬀerent components of the
trigeminovascular system. This might be explained by
the gain-of-function eﬀect on the CaV2.1 calcium chan-
nels that inﬂuence the modulation properties of suma-
triptan, since activation of the 5-HT1 receptor
modulates calcium channels to control CGRP release.35
In conclusion, our data do not support the a priori
hypothesis that the FHM1 R192Q mutation increases
dural artery vasodilation and CGRP release in the tri-
geminovascular system; instead, a decrease in dural
vasodilation and no eﬀect on CGRP release was
observed, possibly involving trigeminovascular CGRP
receptor desensitization. Thus, our data reinforce the
ﬁndings of previous studies that the R192Q mutation
does not only aﬀect central aspects of migraine patho-
physiology, but also the normal functioning of the tri-
geminovascular system. Moreover, the eﬀects of the
mutation on CGRP release in the trigeminovascular
system may not just be an ‘on’ or ‘oﬀ’ phenomenon
but rather of a modulatory nature, involving multiple
mechanisms. Although it is still undeﬁned whether the
trigeminovascular eﬀects of the R192Q mutation are
the consequence of a direct neurovascular eﬀect, a cen-
tral neuronal dysfunction, or a combination of both;
our results clearly indicate that the FHM1 R192Q
mice display trigeminovascular abnormalities, underlin-
ing their relevance for migraine research.
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